Author: "Gamucci, A." - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Gamucci, A."' showing total 1,117 results

Start Over Author "Gamucci, A."

1,117 results on '"Gamucci, A."'

1. Valoración de usuarios y profesionales sanitarios sobre la teleconsulta en Atención Primaria: estudio transversal

Author: Gamucci Jiménez de Parga, Sofia, Garriga Casanovas, Agnès, Gómez Sans, Judith, Aramendía Macua, Javier, Guardiola Sala, Anna, and Orfila Pernas, Francesc
Published: 2023
Full Text: View/download PDF

2. Valoración de usuarios y profesionales sanitarios sobre la teleconsulta en Atención Primaria: estudio transversal

Author: Sofia Gamucci Jiménez de Parga, Agnès Garriga Casanovas, Judith Gómez Sans, Javier Aramendía Macua, Anna Guardiola Sala, and Francesc Orfila Pernas
Subjects: Telemedicine, Primary health care, Patient satisfaction, Medicine (General), R5-920
Abstract: Resumen: Objetivo: Conocer la valoración y preferencias de usuarios y profesionales sanitarios sobre la teleconsulta en Atención Primaria. Diseño: Estudio transversal mediante encuesta, telefónica a usuarios y presencial a profesionales, en 2021. Emplazamiento: Atención Primara urbana. Sujetos: Muestra aleatoria de usuarios con teleconsultas en el último año, estratificados por sexo y edad, y médicos y enfermeros de los centros participantes. Mediciones: Variables Likert valorando la teleconsulta según motivos de consulta, preferencias y aspectos relacionados. Análisis descriptivo y comparación de proporciones y medias. Resultados: Responden 300 pacientes y 48 profesionales. Ambos valoran positivamente la teleconsulta para gestionar la receta electrónica (RE) (el 83 y el 83%, respectivamente), la incapacidad temporal (IT) (el 80 y el 64%) y cuestiones relacionadas con la COVID-19 (el 71 y el 58%). La valoración positiva de la teleconsulta disminuye para el tratamiento de las enfermedades agudas (el 47 y el 25%) y crónicas (el 49 y el 33%). Globalmente las personas
Published: 2023
Full Text: View/download PDF

3. High-yield production of 2D crystals by wet-jet milling

Author: Castillo, Antonio Esau Del Rio, Pellegrini, Vittorio, Ansaldo, Alberto, Ricciardella, Filiberto, Sun, Haiyan, Marasco, Luigi, Buha, Joka, Dang, Zhiya, Gagliani, Luca, Lago, Emanuele, Curreli, Nicola, Gentiluomo, Silvia, Palazon, Francisco, Toth, Peter, Mantero, Elisa, Crugliano, Manuel, Gamucci, Andrea, Tomadin, Andrea, Polini, Marco, and Bonaccorso, Francesco
Subjects: Condensed Matter - Materials Science
Abstract: Efficient and scalable production of two-dimensional (2D) materials is required to overcome technological hurdles towards the creation of a 2D-materials-based industry. Here, we present a novel approach developed for the exfoliation of layered crystals, i.e., graphite, hexagonal boron nitride and transition metal dichalcogenides. The process is based on high-pressure wet-jet-milling (WJM), resulting in 2 L/hr production of 10 g/L of single- and few-layer 2D crystal flakes in dispersion making the scaling-up more affordable. The WJM process enables the production of defect-free and high-quality 2D-crystal dispersions on a large scale, opening the way for the full exploitation in different commercial applications, e.g., anodes active material in lithium ion batteries, reinforcement in polymer-graphene composites, and transparent conductors as we demonstrate in this report., Comment: 30 pages, 15 figures
Published: 2018
Full Text: View/download PDF

4. Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study

Author: Agnese Fabbri, Fabrizio Nelli, Andrea Botticelli, Diana Giannarelli, Eleonora Marrucci, Cristina Fiore, Antonella Virtuoso, Simone Scagnoli, Simona Pisegna, Daniele Alesini, Valentina Sini, Armando Orlandi, Alessandra Fabi, Federico Piacentini, Luca Moscetti, Giuliana D’Auria, Teresa Gamucci, Marco Mazzotta, Laura Pizzuti, Patrizia Vici, Elisabetta Cretella, Paola Scavina, Annalisa La Cesa, Mara Persano, Francesco Atzori, and Enzo Maria Ruggeri
Subjects: pertuzumab, trastuzumab, breast cancer, neoadjuvant chemotherapy, HER-2 positive, real-world data, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract: PurposeClinical trials have shown a significant increase in pathologic complete response (pCR) with the addition of pertuzumab to neoadjuvant chemotherapy for patients with early-stage HER-2 positive breast cancer. To date, limited studies have examined comparative outcomes of neoadjuvant pertuzumab in real-world setting. The Neopearl study aimed to assess comparative real-life efficacy and safety of neoadjuvant pertuzumab for these patients.MethodsWe conducted a nationwide retrospective analysis involving 17 oncology facilities with a certified multidisciplinary breast cancer treatment committee. We identified patients with HER-2 positive stage II-III breast cancer treated with neoadjuvant chemotherapy based on trastuzumab and taxanes with or without pertuzumab. All patients underwent breast surgery and received a comprehensive cardiologic evaluation at baseline and after neoadjuvant treatment. Patients who received the combination of pertuzumab, trastuzumab, and chemotherapy constituted case cohort (PTCT), whereas those treated with trastuzumab and chemotherapy accounted for control cohort (TCT). The pCR rate and 5-year event free survival (EFS) were the primary outcomes. Secondary end-points were rates of conversion from planned modified radical mastectomy (MRM) to breast conservation surgery (BCS) and cardiotoxicities.ResultsFrom March 2014 to April 2021, we included 271 patients, 134 (49%) and 137 (51%) in TCT and PTCT cohort, respectively. Positive axillary lymph nodes and stage III were more frequent in PTCT cohort. The pCR rate was significantly increased in patients who received pertuzumab (49% vs 62%; OR 1.74, 95%CI 1.04-2.89) and with HER-2 enriched subtypes (16% vs 85%; OR 2.94, 95%CI 1.60-5.41). After a median follow-up of 5 years, the 5-year EFS was significantly prolonged only in patients treated with pertuzumab (81% vs 93%; HR 2.22, 95%CI 1.03-4.79). The same analysis performed on propensity score matched population showed concordant results. On univariate analysis, only patients with positive lymph nodes were found to benefit from pertuzumab for both pCR and 5-year EFS. The rates of conversion from MRM to BCS and cardiologic toxicities did not differ between the cohorts.ConclusionOur findings support previous data on improved outcomes with the addition of pertuzumab to trastuzumab-based neoadjuvant chemotherapy. This benefit seems to be more significant in patients with clinically positive lymph nodes.
Published: 2023
Full Text: View/download PDF

5. Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study

Author: Francesca Sofia Di Lisa, Eriseld Krasniqi, Laura Pizzuti, Maddalena Barba, Katia Cannita, Ugo De Giorgi, Fulvio Borella, Jennifer Foglietta, Anna Cariello, Antonella Ferro, Elisa Picardo, Marco Mitidieri, Valentina Sini, Simonetta Stani, Giuseppe Tonini, Daniele Santini, Nicla La Verde, Anna Rita Gambaro, Antonino Grassadonia, Nicola Tinari, Ornella Garrone, Giuseppina Sarobba, Lorenzo Livi, Icro Meattini, Giuliana D’Auria, Matteo Vergati, Teresa Gamucci, Mirco Pistelli, Rossana Berardi, Emanuela Risi, Francesco Giotta, Vito Lorusso, Lucia Rinaldi, Salvatore Artale, Marina Elena Cazzaniga, Fable Zustovich, Federico Cappuzzo, Lorenza Landi, Rosalba Torrisi, Simone Scagnoli, Andrea Botticelli, Andrea Michelotti, Beatrice Fratini, Rosa Saltarelli, Ida Paris, Margherita Muratore, Alessandra Cassano, Lorenzo Gianni, Valeria Gaspari, Enzo Maria Veltri, Federica Zoratto, Elena Fiorio, Maria Agnese Fabbri, Marco Mazzotta, Enzo Maria Ruggeri, Rebecca Pedersini, Maria Rosaria Valerio, Lorena Filomeno, Mauro Minelli, Paola Scavina, Mimma Raffaele, Antonio Astone, Roy De Vita, Marcello Pozzi, Ferdinando Riccardi, Filippo Greco, Luca Moscetti, Monica Giordano, Marcello Maugeri-Saccà, Alessandro Zennaro, Claudio Botti, Fabio Pelle, Sonia Cappelli, Flavia Cavicchi, Enrico Vizza, Giuseppe Sanguineti, Federica Tomao, Enrico Cortesi, Paolo Marchetti, Silverio Tomao, Iolanda Speranza, Isabella Sperduti, Gennaro Ciliberto, and Patrizia Vici
Subjects: triple negative breast cancer, neoadjuvant treatment, residual tumors, adjuvant capecitabine, treatment discontinuation, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract: BackgroundIn triple negative breast cancer patients treated with neoadjuvant chemotherapy, residual disease at surgery is the most relevant unfavorable prognostic factor. Current guidelines consider the use of adjuvant capecitabine, based on the results of the randomized CREATE-X study, carried out in Asian patients and including a small subset of triple negative tumors. Thus far, evidence on Caucasian patients is limited, and no real-world data are available.MethodsWe carried out a multicenter, observational study, involving 44 oncologic centres. Triple negative breast cancer patients with residual disease, treated with adjuvant capecitabine from January 2017 through June 2021, were recruited. We primarily focused on treatment tolerability, with toxicity being reported as potential cause of treatment discontinuation. Secondarily, we assessed effectiveness in the overall study population and in a subset having a minimum follow-up of 2 years.ResultsOverall, 270 patients were retrospectively identified. The 50.4% of the patients had residual node positive disease, 7.8% and 81.9% had large or G3 residual tumor, respectively, and 80.4% a Ki-67 >20%. Toxicity-related treatment discontinuation was observed only in 10.4% of the patients. In the whole population, at a median follow-up of 15 months, 2-year disease-free survival was 62%, 2 and 3-year overall survival 84.0% and 76.2%, respectively. In 129 patients with a median follow-up of 25 months, 2-year disease-free survival was 43.4%, 2 and 3-year overall survival 78.0% and 70.8%, respectively. Six or more cycles of capecitabine were associated with more favourable outcomes compared with less than six cycles.ConclusionThe CaRe study shows an unexpectedly good tolerance of adjuvant capecitabine in a real-world setting, although effectiveness appears to be lower than that observed in the CREATE-X study. Methodological differences between the two studies impose significant limits to comparability concerning effectiveness, and strongly invite further research.
Published: 2023
Full Text: View/download PDF

6. Transport in strongly-coupled graphene-LaAlO3/SrTiO3 hybrid systems

Author: Aliaj, I., Torre, I., Miseikis, V., di Gennaro, E., Sambri, A., Gamucci, A., Coletti, C., Beltram, F., Granozio, F. M., Polini, M., Pellegrini, V., and Roddaro, S.
Subjects: Condensed Matter - Mesoscale and Nanoscale Physics
Abstract: We report on the transport properties of hybrid devices obtained by depositing graphene on a LaAlO3/SrTiO3 oxide junction hosting a 4 nm-deep two-dimensional electron system. At low graphene-oxide inter-layer bias the two electron systems are electrically isolated, despite their small spatial separation, and very efficient reciprocal gating is shown. A pronounced rectifying behavior is observed for larger bias values and ascribed to the interplay between electrostatic depletion and tunneling across the LaAlO3 barrier. The relevance of these results in the context of strongly-coupled bilayer systems is discussed., Comment: 10 pages, 3 figures
Published: 2016
Full Text: View/download PDF

7. MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study

Author: E. Krasniqi, A. Sacconi, D. Marinelli, L. Pizzuti, M. Mazzotta, D. Sergi, E. Capomolla, S. Donzelli, M. Carosi, A. Bagnato, T. Gamucci, S. Tomao, C. Natoli, P. Marchetti, A. Grassadonia, N. Tinari, M. De Tursi, E. Vizza, G. Ciliberto, L. Landi, F. Cappuzzo, M. Barba, G. Blandino, and P. Vici
Subjects: Ovarian cancer, miRNAs, Prognostic/predictive biomarkers, Therapeutics. Pharmacology, RM1-950
Abstract: Abstract Background In Western countries, ovarian cancer (OC) still represents the leading cause of gynecological cancer-related deaths, despite the remarkable gains in therapeutical options. Novel biomarkers of early diagnosis, prognosis definition and prediction of treatment outcomes are of pivotal importance. Prior studies have shown the potentials of micro-ribonucleic acids (miRNAs) as biomarkers for OC and other cancers. Methods We focused on the prognostic and/or predictive potential of miRNAs in OC by conducting a comprehensive array profiling of miRNA expression levels in ovarian tissue samples from 17 non-neoplastic controls, and 60 tumor samples from OC patients treated at the Regina Elena National Cancer Institute (IRE). A set of 54 miRNAs with differential expression in tumor versus normal samples (T/N-deregulated) was identified in the IRE cohort and validated against data from the Cancer Genoma Atlas (TCGA) related to 563 OC patients and 8 non-neoplastic controls. The prognostic/predictive role of the selected 54 biomarkers was tested in reference to survival endpoints and platinum resistance (P-res). Results In the IRE cohort, downregulation of the 2 miRNA-signature including miR-99a-5p and miR-320a held a negative prognostic relevance, while upregulation of miR-224-5p was predictive of less favorable event free survival (EFS) and P-res. Data from the TCGA showed that downregulation of 5 miRNAs, i.e., miR-150, miR-30d, miR-342, miR-424, and miR-502, was associated with more favorable EFS and overall survival outcomes, while miR-200a upregulation was predictive of P-res. The 9 miRNAs globally identified were all included into a single biologic signature, which was tested in enrichment analysis using predicted/validated miRNA target genes, followed by network representation of the miRNA-mRNA interactions. Conclusions Specific dysregulated microRNA sets in tumor tissue showed predictive/prognostic value in OC, and resulted in a promising biological signature for this disease.
Published: 2021
Full Text: View/download PDF

8. The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial

Author: Laura Pizzuti, Maddalena Barba, Marco Mazzotta, Eriseld Krasniqi, Marcello Maugeri-Saccà, Teresa Gamucci, Rossana Berardi, Lorenzo Livi, Corrado Ficorella, Clara Natoli, Enrico Cortesi, Daniele Generali, Nicla La Verde, Alessandra Cassano, Emilio Bria, Luca Moscetti, Andrea Michelotti, Vincenzo Adamo, Claudio Zamagni, Giuseppe Tonini, Domenico Sergi, Daniele Marinelli, Giancarlo Paoletti, Silverio Tomao, Andrea Botticelli, Paolo Marchetti, Nicola Tinari, Antonino Grassadonia, Maria Rosaria Valerio, Rosanna Mirabelli, Maria Agnese Fabbri, Nicola D’Ostilio, Enzo Veltri, Domenico Corsi, Ornella Garrone, Ida Paris, Giuseppina Sarobba, Icro Meattini, Mirco Pistelli, Francesco Giotta, Vito Lorusso, Carlo Garufi, Antonio Russo, Marina Cazzaniga, Pietro Del Medico, Mario Roselli, Angela Vaccaro, Letizia Perracchio, Anna di Benedetto, Theodora Daralioti, Isabella Sperduti, Ruggero De Maria, Angelo Di Leo, Giuseppe Sanguineti, Gennaro Ciliberto, and Patrizia Vici
Subjects: Medicine, Science
Abstract: Abstract In metastatic breast cancer (mBC), the change of human epidermal growth factor receptor 2 (HER2) status between primary and metastatic lesions is widely recognized, however clinical implications are unknown. Our study address the question if relevant differences exist between subjects who preserve the HER2 status and those who gain the HER2 positivity when relapsed. Data of patients affected by HER2-positive mBC, treated with pertuzumab and/or trastuzumab-emtansine (T-DM1) in a real-world setting at 45 Italian cancer centers were retrospectively collected and analyzed. From 2003 to 2017, 491 HER2‐positive mBC patients were included. Of these, 102 (20.7%) had been initially diagnosed as HER2-negative early BC. Estrogen and/or progesterone receptor were more expressed in patients with HER2-discordance compared to patients with HER2-concordant status (p
Published: 2021
Full Text: View/download PDF

9. Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)

Author: De Angelis, C., Bruzzese, D., Bernardo, A., Baldini, E., Leo, L., Fabi, A., Gamucci, T., De Placido, P., Poggio, F., Russo, S., Forestieri, V., Lauria, R., De Santo, I., Michelotti, A., Del Mastro, L., De Laurentiis, M., Giuliano, M., De Placido, S., and Arpino, G.
Published: 2021
Full Text: View/download PDF

10. Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer

Author: Fabio Puglisi, Lorenzo Gerratana, Matteo Lambertini, Marcello Ceppi, Luca Boni, Filippo Montemurro, Stefania Russo, Claudia Bighin, Michelino De Laurentiis, Mario Giuliano, Giancarlo Bisagni, Antonio Durando, Anna Turletti, Ornella Garrone, Andrea Ardizzoni, Teresa Gamucci, Giuseppe Colantuoni, Adriano Gravina, Sabino De Placido, Francesco Cognetti, and Lucia Del Mastro
Subjects: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract: Abstract The GIM2 phase III trial demonstrated the benefit of dose-dense chemotherapy in node-positive early breast cancer (eBC). To better define the dose-dense effect in the hormone receptor-positive subgroup, we evaluated its benefit through a composite measure of recurrence risk. We conducted an ancillary analysis of the GIM2 trial evaluating the absolute treatment effect through a composite measure of recurrence risk (CPRS) in patients with hormone receptor-positive HER2-negative eBC. CPRS was estimated through Cox proportional hazards models applied to the different clinicopathological features. The treatment effect was compared to the values of CPRS by using the Sub-population Treatment Effect Pattern Plot (STEPP) process. The Disease-Free Survival (DFS)-oriented STEPP analysis showed distinct patterns of relative treatment effect with respect to CPRS. Overall, 5-year DFS differed across CPRS quartiles ranging from 95.2 to 66.4%. Each CPRS quartile was characterized by a different patients’ composition, especially for age, lymph node involvement, tumor size, estrogen and progesterone receptor expression, and Ki-67. A number needed to treat of 154 and 6 was associated with the lowest and the highest CPRS quartile, respectively. Dose-dense adjuvant chemotherapy showed a consistent benefit in node-positive eBC patients with hormone receptor-positive HER2-negative disease, but its effect varied according to CPRS.
Published: 2021
Full Text: View/download PDF

11. PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy

Author: Francesco Cognetti, Riccardo Masetti, Alessandra Fabi, Giulia Bianchi, Donatella Santini, Alessia Rognone, Giovanna Catania, Domenico Angelucci, Giuseppe Naso, Mario Giuliano, Lucia Vassalli, Patrizia Vici, Giovanni Scognamiglio, Daniele Generali, Alberto Zambelli, Marco Colleoni, Corrado Tinterri, Francesco Scanzi, Leonardo Vigna, Paola Scavina, Teresa Gamucci, Emilia Marrazzo, Angelo Fedele Scinto, Rossana Berardi, Maria Agnese Fabbri, Graziella Pinotti, Daniela Franco, Daniela Andreina Terribile, Giuseppe Tonini, Daniela Cianniello, and Sandro Barni
Subjects: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract: Abstract Clinicopathological prognostic features have limited value to identify with precision newly diagnosed patients with hormone receptor (HR)-positive, HER2-negative breast cancer (BC), who would benefit from chemotherapy (CT) in addition to adjuvant hormonal therapy (HT). The 21-gene Oncotype DX Breast Recurrence Score® (RS) assay has been demonstrated to predict CT benefit, hence supporting personalized decisions on adjuvant CT. The multicenter, prospective, observational study PONDx investigated the real-life use of RS® results in Italy and its impact on treatment decisions. Physicians’ treatment recommendations (HT ± CT) were documented before and after availability of RS results, and changes in recommendations were determined. In the HR+ HER2− early BC population studied (N = 1738), physicians recommended CT + HT in 49% of patients pre-RS. RS-guided treatment decisions resulted in 36% reduction of CT recommendations. PONDx confirms that RS results provide clinically relevant information for CT recommendation in early-stage BC, resulting in a reduction of more than a third of CT use.
Published: 2021
Full Text: View/download PDF

12. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Author: Agajanian, Richy, Ahmad, Rizvana, Aktas, Bahriye, Alencar, Victor Hugo, Amadori, Dino, Andrade, Jurandyr, André Franke, Fábio, Angiolini, Catia, Aogi, Kenjiro, Armor, Jess, Arpornwirat, Wichit, Assersohn, Laura, Audeh, William, Aulitzky, Walter, Azevedo, Sergio, Bartoli, Maria Alejandra, Batista Lopez, Norberto, Bianconi, María, Biganzoli, Laura, Birhiray, Ruemu, Bitina, Marianna, Blachy, Ron, Blackwell, Kimberly, Blanchard, Rita, Blanchet, Paulette, Boiangiu, Ion, Bower, Barbara, Brezden-Masley, Christine, Brufsky, Adam, Budde, Leanne, Caguioa, Priscilla, Calvo, Lourdes, Campone, Mario, Carroll, Robert R., Castro, Hugo, Chan, Valorie, Charu, Veena, Cinieri, Saverio, Clemens, Michael, Conejo, Emilio Alba, Côrtes, Eduardo, Coudert, Bruno, Cronemberger, Eduardo, Cubero, Daniel, Dakhil, Shaker, Daniel, Brooke, Davidson, Neville, De Fatima Gaui, Maria, De La Cruz, Susana, Del Pilar, Maria, Delgado, Gilson, Ellerton, John A., Estuardo, Cesar, Fehrenbacher, Louis, Ferrero, Jean-Marc, Flynn, Patrick J., Foszczynska-Kloda, Malgorzata, Franco, Sandra, Fujii, Hirofumi, Gallagher, Chris, Gamucci, Teresa, Giacomi, Nora, Gil I Gil, Miguel, Gonzalez Martin, Antonio, Gorbunova, Vera, Gotovkin, Eugeny, Green, Nathan, Grincuka, Elza, Grischke, Eva-Maria, Hansen, Vincent, Hargis, Jeffrey, Hauschild, Maik, Hegg, Roberto, Hendricks, Carolyn, Hermann, Robert, Hoff, Paulo, Horiguchi, Jun, Hornedo Muguiro, Javier, Iacobelli, Stefano, Inoue, Kenichi, Ismael, Gustavo, Itoh, Yoshinori, Iwata, Dr Hiroji, Jendiroba, Davi, Jochim, Rosa, Jones, Alison, Just, Marianne, Kallab, Andre, Karwal, Mark, Kashiwaba, Masahiro, Kato, Giraldo, Kaufman, Peter A., Kellokumpu-Lehtinen, Pirkko, Kirsch, Andreas, Kiselev, Igor, Klein, Paula, Kohno, Norio, Kopp, Mikhail, Kostovska-Maneva, Liljana, Kotliar, Mauricio, Kudaba, Iveta, Kümmel, Sherko, Kuroi, Katsumasa, Lacava, Juan, Latini, Luciano, Lee, Soo Chin, Lichinitser, Mikhail, Lobo, Christopher, Maintz, Christoph, Maneecahvakajorn, Jedzada, Marmé, Alexander, Martinez, Gloria, Masuda, Norikazu, Matwiejuk, Mario, Merculov, Vladimir, Michaelson, Richard, Miguel, Luis, Monroy, Hernandez, Montemurro, Filippo, Morales, Serafin, Moura, Rodrigo, Mueller, Volkmar, Mulatero, Clive, Nakagami, Kazuhiko, Nakayama, Takahiro, Neidhart, Jeff, Nguyen, An, Nishimura, Reiki, Ogata, Haruki, O'reilly, Susan, O'rourke, Timothy, Otero Reye, Douglas, Ouyang, Xuenong, Patel, Ravi, Patel, Taral, Pedrini, Jose Luiz, Pereira, Rodrigo, Perez, Alejandra, Peterson, Carol, Pienkowski, Tadeusz, Pinczowski, Helio, Polikoff, Jonathan, Polkowski, Wojciech, Price, Paola Edith, Prill, Sue, Priou, Frank, Purkalne, Gunta, Pyrhoenen, Seppo, Quackenbush, Robert, Rai, Yoshiaki, Ribelles, Nuria, Ro, Jungsil, Robinson, Anne, Robles, Robert, Rodriguez, Gladys, Roman, Laslo, Saji, Shigehira, Sanchez-Rovira, Pedro, Sato, Nobuaki, Schmidt, Marcus, Schumacher, Claudia, Senecal, Frank, Sharma, Priyanka, Shen, Zhenzhou, Shirinkin, Vadim, Simoncini, Edda, Sirisinha, Thitiya, Smith, Raymond, Sohn, Joo-Hyuk, Soldic, Zeljko, Soria, Tania, Spicer, Darcy, Srimuninnimit, Vichien, Sriuranpong, Virote, Staroslawska, Elzbieta, Stefanovski, Petar, Sunpaweravong, Patrapim, Taguchi, Julie, Takeda, Koji, Tellez-Trevilla, Gabriel, Thomas, Randall, Thomssen, Christoph, Toache, Zetina, Tokuda, Yutaka, Tomczak, Piotr, Tosello, Celia, Tsugawa, Koichiro, Tudtud, Dennis, Ueno, Takayuki, Van Eyll, Brigitte, Varela, Mirta, Vasev, Nikola, Vrbanec, Damir, Wang, Xiaojia, Wang, Liwei, Watanabe, Junichiro, Waterhouse, David, Wesenberg, Birgitta, Wheatley, Duncan, Wong, Zee Wan, Yadav, Sanjay, Yardley, Denise, Yau, Tsz-Kok, Yeo, Winnie, Ying, Cheng, Youn Oh, Do, Swain, Sandra M, Miles, David, Kim, Sung-Bae, Im, Young-Hyuck, Im, Seock-Ah, Semiglazov, Vladimir, Ciruelos, Eva, Schneeweiss, Andreas, Loi, Sherene, Monturus, Estefanía, Clark, Emma, Knott, Adam, Restuccia, Eleonora, Benyunes, Mark C, and Cortés, Javier
Published: 2020
Full Text: View/download PDF

13. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Author: Falcone, Alfredo, Lonardi, Sara, De Braud, Filippo Guglielmo Maria, Bordonaro, Roberto, Maiello, Evaristo, Tamburini, Emiliano, Santini, Daniele, Frassineti, Giovanni Luca, Gamucci, Teresa, Aprile, Giuseppe, Zaniboni, Alberto, Granetto, Cristina, Buonadonna, Angela, Di Costanzo, Francesco, Tomasello, Gianluca, Gianni, Luca, Di Donato, Samantha, Carlomagno, Chiara, Clavarezza, Matteo, Racca, Patrizia, Mambrini, Andrea, Roselli, Mario, Allegrini, Giacomo, Sobrero, Alberto, Aglietta, Massimo, Corgna, Enrichetta, Cortesi, Enrico, Corsi, Domenico Cristiano, Ballestrero, Alberto, Bonetti, Andrea, Di Clemente, Francesco, Ruggeri, Enzo, Ciardiello, Fortunato, Benasso, Marco, Vitello, Stefano, Cinieri, Saverio, Mosconi, Stefania, Silvestris, Nicola, Frassoldati, Antonio, Cupini, Samantha, Bertolini, Alessandro, Tortora, Giampaolo, Bengala, Carmelo, Ferrari, Daris, Ardizzoia, Antonia, Milandri, Carlo, Chiara, Silvana, Romano, Gianpiero, Miraglia, Stefania, Scaltriti, Laura, Pucci, Francesca, Blasi, Livio, Brugnatelli, Silvia, Fioretto, Luisa, Ribecco, Angela Stefania, Longarini, Raffaella, Frisinghelli, Michela, Banzi, Maria, Cremolini, Chiara, Antoniotti, Carlotta, Rossini, Daniele, Loupakis, Fotios, Pietrantonio, Filippo, Latiano, Tiziana Pia, Passardi, Alessandro, Marmorino, Federica, Grande, Roberta, Murgioni, Sabina, Moretto, Roberto, Corallo, Salvatore, Cordio, Stefano, Antonuzzo, Lorenzo, Masi, Gianluca, Ronzoni, Monica, Ritorto, Giuliana, Cupini, Samanta, Mammoliti, Serafina, Fenocchio, Elisabetta, Zagonel, Vittorina, Fontanini, Gabriella, Ugolini, Clara, and Boni, Luca
Published: 2020
Full Text: View/download PDF

14. Electron-hole pairing in graphene-GaAs heterostructures

Author: Gamucci, A., Spirito, D., Carrega, M., Karmakar, B., Lombardo, A., Bruna, M., Ferrari, A. C., Pfeiffer, L. N., West, K. W., Polini, Marco, and Pellegrini, V.
Subjects: Condensed Matter - Mesoscale and Nanoscale Physics
Abstract: Vertical heterostructures combining different layered materials offer novel opportunities for applications and fundamental studies of collective behavior driven by inter-layer Coulomb coupling. Here we report heterostructures comprising a single-layer (or bilayer) graphene carrying a fluid of massless (massive) chiral carriers, and a quantum well created in GaAs 31.5 nm below the surface, supporting a high-mobility two-dimensional electron gas. These are a new class of double-layer devices composed of spatially-separated electron and hole fluids. We find that the Coulomb drag resistivity significantly increases for temperatures below 5-10 K, following a logarithmic law. This anomalous behavior is a signature of the onset of strong inter-layer correlations, compatible with the formation of a condensate of permanent excitons. The ability to induce strongly-correlated electron-hole states paves the way for the realization of coherent circuits with minimal dissipation and nanodevices including analog-to-digital converters and topologically protected quantum bits., Comment: 9 pages, 9 figures, 72 references
Published: 2014
Full Text: View/download PDF

15. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

Author: Giulia Bon, Laura Pizzuti, Valentina Laquintana, Rossella Loria, Manuela Porru, Caterina Marchiò, Eriseld Krasniqi, Maddalena Barba, Marcello Maugeri-Saccà, Teresa Gamucci, Rossana Berardi, Lorenzo Livi, Corrado Ficorella, Clara Natoli, Enrico Cortesi, Daniele Generali, Nicla La Verde, Alessandra Cassano, Emilio Bria, Luca Moscetti, Andrea Michelotti, Vincenzo Adamo, Claudio Zamagni, Giuseppe Tonini, Giacomo Barchiesi, Marco Mazzotta, Daniele Marinelli, Silverio Tomao, Paolo Marchetti, Maria Rosaria Valerio, Rosanna Mirabelli, Antonio Russo, Maria Agnese Fabbri, Nicola D’Ostilio, Enzo Veltri, Domenico Corsi, Ornella Garrone, Ida Paris, Giuseppina Sarobba, Francesco Giotta, Carlo Garufi, Marina Cazzaniga, Pietro Del Medico, Mario Roselli, Giuseppe Sanguineti, Isabella Sperduti, Anna Sapino, Ruggero De Maria, Carlo Leonetti, Angelo Di Leo, Gennaro Ciliberto, Rita Falcioni, and Patrizia Vici
Subjects: HER2+ breast cancer, Trastuzumab/pertuzumab blockade, T-DM1 efficacy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract: Abstract Background HER2-targeting agents have dramatically changed the therapeutic landscape of HER2+ advanced breast cancer (ABC). Within a short time frame, the rapid introduction of new therapeutics has led to the approval of pertuzumab combined with trastuzumab and a taxane in first-line, and trastuzumab emtansine (T-DM1) in second-line. Thereby, evidence of T-DM1 efficacy following trastuzumab/pertuzumab combination is limited, with data from some retrospective reports suggesting lower activity. The purpose of the present study is to investigate T-DM1 efficacy in pertuzumab-pretreated and pertuzumab naïve HER2 positive ABC patients. We also aimed to provide evidence on the exposure to different drugs sequences including pertuzumab and T-DM1 in HER2 positive cell lines. Methods The biology of HER2 was investigated in vitro through sequential exposure of resistant HER2 + breast cancer cell lines to trastuzumab, pertuzumab, and their combination. In vitro experiments were paralleled by the analysis of data from 555 HER2 + ABC patients treated with T-DM1 and evaluation of T-DM1 efficacy in the 371 patients who received it in second line. Survival estimates were graphically displayed in Kaplan Meier curves, compared by log rank test and, when possibile, confirmed in multivariate models. Results We herein show evidence of lower activity of T-DM1 in two HER2+ breast cancer cell lines resistant to trastuzumab+pertuzumab, as compared to trastuzumab-resistant cells. Lower T-DM1 efficacy was associated with a marked reduction of HER2 expression on the cell membrane and its nuclear translocation. HER2 downregulation at the membrane level was confirmed in biopsies of four trastuzumab/pertuzumab-pretreated patients. Among the 371 patients treated with second-line T-DM1, median overall survival (mOS) from diagnosis of advanced disease and median progression-free survival to second-line treatment (mPFS2) were 52 and 6 months in 177 patients who received trastuzumab/pertuzumab in first-line, and 74 and 10 months in 194 pertuzumab-naïve patients (p = 0.0006 and 0.03 for OS and PFS2, respectively). Conclusions Our data support the hypothesis that the addition of pertuzumab to trastuzumab reduces the amount of available plasma membrane HER2 receptor, limiting the binding of T-DM1 in cancer cells. This may help interpret the less favorable outcomes of second-line T-DM1 in trastuzumab/pertuzumab pre-treated patients compared to their pertuzumab-naïve counterpart.
Published: 2020
Full Text: View/download PDF

16. Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study

Author: Di Lisa, F, Krasniqi, E, Pizzuti, L, Barba, M, Cannita, K, De Giorgi, U, Borella, F, Foglietta, J, Cariello, A, Ferro, A, Picardo, E, Mitidieri, M, Sini, V, Stani, S, Tonini, G, Santini, D, La Verde, N, Gambaro, A, Grassadonia, A, Tinari, N, Garrone, O, Sarobba, G, Livi, L, Meattini, I, D'Auria, G, Vergati, M, Gamucci, T, Pistelli, M, Berardi, R, Risi, E, Giotta, F, Lorusso, V, Rinaldi, L, Artale, S, Cazzaniga, M, Zustovich, F, Cappuzzo, F, Landi, L, Torrisi, R, Scagnoli, S, Botticelli, A, Michelotti, A, Fratini, B, Saltarelli, R, Paris, I, Muratore, M, Cassano, A, Gianni, L, Gaspari, V, Veltri, E, Zoratto, F, Fiorio, E, Fabbri, M, Mazzotta, M, Ruggeri, E, Pedersini, R, Valerio, M, Filomeno, L, Minelli, M, Scavina, P, Raffaele, M, Astone, A, De Vita, R, Pozzi, M, Riccardi, F, Greco, F, Moscetti, L, Giordano, M, Maugeri-Sacca, M, Zennaro, A, Botti, C, Pelle, F, Cappelli, S, Cavicchi, F, Vizza, E, Sanguineti, G, Tomao, F, Cortesi, E, Marchetti, P, Tomao, S, Speranza, I, Sperduti, I, Ciliberto, G, Vici, P, Di Lisa F. S., Krasniqi E., Pizzuti L., Barba M., Cannita K., De Giorgi U., Borella F., Foglietta J., Cariello A., Ferro A., Picardo E., Mitidieri M., Sini V., Stani S., Tonini G., Santini D., La Verde N., Gambaro A. R., Grassadonia A., Tinari N., Garrone O., Sarobba G., Livi L., Meattini I., D'Auria G., Vergati M., Gamucci T., Pistelli M., Berardi R., Risi E., Giotta F., Lorusso V., Rinaldi L., Artale S., Cazzaniga M. E., Zustovich F., Cappuzzo F., Landi L., Torrisi R., Scagnoli S., Botticelli A., Michelotti A., Fratini B., Saltarelli R., Paris I., Muratore M., Cassano A., Gianni L., Gaspari V., Veltri E. M., Zoratto F., Fiorio E., Fabbri M. A., Mazzotta M., Ruggeri E. M., Pedersini R., Valerio M. R., Filomeno L., Minelli M., Scavina P., Raffaele M., Astone A., De Vita R., Pozzi M., Riccardi F., Greco F., Moscetti L., Giordano M., Maugeri-Sacca M., Zennaro A., Botti C., Pelle F., Cappelli S., Cavicchi F., Vizza E., Sanguineti G., Tomao F., Cortesi E., Marchetti P., Tomao S., Speranza I., Sperduti I., Ciliberto G., Vici P., Di Lisa, F, Krasniqi, E, Pizzuti, L, Barba, M, Cannita, K, De Giorgi, U, Borella, F, Foglietta, J, Cariello, A, Ferro, A, Picardo, E, Mitidieri, M, Sini, V, Stani, S, Tonini, G, Santini, D, La Verde, N, Gambaro, A, Grassadonia, A, Tinari, N, Garrone, O, Sarobba, G, Livi, L, Meattini, I, D'Auria, G, Vergati, M, Gamucci, T, Pistelli, M, Berardi, R, Risi, E, Giotta, F, Lorusso, V, Rinaldi, L, Artale, S, Cazzaniga, M, Zustovich, F, Cappuzzo, F, Landi, L, Torrisi, R, Scagnoli, S, Botticelli, A, Michelotti, A, Fratini, B, Saltarelli, R, Paris, I, Muratore, M, Cassano, A, Gianni, L, Gaspari, V, Veltri, E, Zoratto, F, Fiorio, E, Fabbri, M, Mazzotta, M, Ruggeri, E, Pedersini, R, Valerio, M, Filomeno, L, Minelli, M, Scavina, P, Raffaele, M, Astone, A, De Vita, R, Pozzi, M, Riccardi, F, Greco, F, Moscetti, L, Giordano, M, Maugeri-Sacca, M, Zennaro, A, Botti, C, Pelle, F, Cappelli, S, Cavicchi, F, Vizza, E, Sanguineti, G, Tomao, F, Cortesi, E, Marchetti, P, Tomao, S, Speranza, I, Sperduti, I, Ciliberto, G, Vici, P, Di Lisa F. S., Krasniqi E., Pizzuti L., Barba M., Cannita K., De Giorgi U., Borella F., Foglietta J., Cariello A., Ferro A., Picardo E., Mitidieri M., Sini V., Stani S., Tonini G., Santini D., La Verde N., Gambaro A. R., Grassadonia A., Tinari N., Garrone O., Sarobba G., Livi L., Meattini I., D'Auria G., Vergati M., Gamucci T., Pistelli M., Berardi R., Risi E., Giotta F., Lorusso V., Rinaldi L., Artale S., Cazzaniga M. E., Zustovich F., Cappuzzo F., Landi L., Torrisi R., Scagnoli S., Botticelli A., Michelotti A., Fratini B., Saltarelli R., Paris I., Muratore M., Cassano A., Gianni L., Gaspari V., Veltri E. M., Zoratto F., Fiorio E., Fabbri M. A., Mazzotta M., Ruggeri E. M., Pedersini R., Valerio M. R., Filomeno L., Minelli M., Scavina P., Raffaele M., Astone A., De Vita R., Pozzi M., Riccardi F., Greco F., Moscetti L., Giordano M., Maugeri-Sacca M., Zennaro A., Botti C., Pelle F., Cappelli S., Cavicchi F., Vizza E., Sanguineti G., Tomao F., Cortesi E., Marchetti P., Tomao S., Speranza I., Sperduti I., Ciliberto G., and Vici P.
Abstract: Background: In triple negative breast cancer patients treated with neoadjuvant chemotherapy, residual disease at surgery is the most relevant unfavorable prognostic factor. Current guidelines consider the use of adjuvant capecitabine, based on the results of the randomized CREATE-X study, carried out in Asian patients and including a small subset of triple negative tumors. Thus far, evidence on Caucasian patients is limited, and no real-world data are available. Methods: We carried out a multicenter, observational study, involving 44 oncologic centres. Triple negative breast cancer patients with residual disease, treated with adjuvant capecitabine from January 2017 through June 2021, were recruited. We primarily focused on treatment tolerability, with toxicity being reported as potential cause of treatment discontinuation. Secondarily, we assessed effectiveness in the overall study population and in a subset having a minimum follow-up of 2 years. Results: Overall, 270 patients were retrospectively identified. The 50.4% of the patients had residual node positive disease, 7.8% and 81.9% had large or G3 residual tumor, respectively, and 80.4% a Ki-67 >20%. Toxicity-related treatment discontinuation was observed only in 10.4% of the patients. In the whole population, at a median follow-up of 15 months, 2-year disease-free survival was 62%, 2 and 3-year overall survival 84.0% and 76.2%, respectively. In 129 patients with a median follow-up of 25 months, 2-year disease-free survival was 43.4%, 2 and 3-year overall survival 78.0% and 70.8%, respectively. Six or more cycles of capecitabine were associated with more favourable outcomes compared with less than six cycles. Conclusion: The CaRe study shows an unexpectedly good tolerance of adjuvant capecitabine in a real-world setting, although effectiveness appears to be lower than that observed in the CREATE-X study. Methodological differences between the two studies impose significant limits to comparability concerning ef
Published: 2023

17. PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting

Author: Laura Pizzuti, Eriseld Krasniqi, Isabella Sperduti, Maddalena Barba, Teresa Gamucci, Maria Mauri, Enzo Maria Veltri, Icro Meattini, Rossana Berardi, Francesca Sofia Di Lisa, Clara Natoli, Mirco Pistelli, Laura Iezzi, Emanuela Risi, Nicola D’Ostilio, Silverio Tomao, Corrado Ficorella, Katia Cannita, Ferdinando Riccardi, Alessandra Cassano, Emilio Bria, Maria Agnese Fabbri, Marco Mazzotta, Giacomo Barchiesi, Andrea Botticelli, Giuliana D’Auria, Anna Ceribelli, Andrea Michelotti, Antonio Russo, Beatrice Taurelli Salimbeni, Giuseppina Sarobba, Francesco Giotta, Ida Paris, Rosa Saltarelli, Daniele Marinelli, Domenico Corsi, Elisabetta Maria Capomolla, Valentina Sini, Luca Moscetti, Lucia Mentuccia, Giuseppe Tonini, Mimma Raffaele, Luca Marchetti, Mauro Minelli, Enzo Maria Ruggeri, Paola Scavina, Olivia Bacciu, Nello Salesi, Lorenzo Livi, Nicola Tinari, Antonino Grassadonia, Angelo Fedele Scinto, Rosalinda Rossi, Maria Rosaria Valerio, Elisabetta Landucci, Simonetta Stani, Beatrice Fratini, Marcello Maugeri-Saccà, Michele De Tursi, Angela Maione, Daniele Santini, Armando Orlandi, Vito Lorusso, Enrico Cortesi, Giuseppe Sanguineti, Paola Pinnarò, Federico Cappuzzo, Lorenza Landi, Claudio Botti, Federica Tomao, Sonia Cappelli, Giulia Bon, Fabio Pelle, Flavia Cavicchi, Elena Fiorio, Jennifer Foglietta, Simone Scagnoli, Paolo Marchetti, Gennaro Ciliberto, and Patrizia Vici
Subjects: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract: Background: The evolution of therapeutic landscape of human epidermal growth factor receptor-2 (HER2)-positive breast cancer (BC) has led to an unprecedented outcome improvement, even if the optimal sequence strategy is still debated. To address this issue and to provide a picture of the advancement of anti-HER2 treatments, we performed a large, multicenter, retrospective study of HER2-positive BC patients. Methods: The observational PANHER study included 1,328 HER2-positive advanced BC patients treated with HER2 blocking agents since June 2000 throughout July 2020. Endpoints of efficacy were progression-free survival (PFS) and overall survival (OS). Results: Patients who received a first-line pertuzumab-based regimen showed better PFS ( p < 0.0001) and OS ( p = 0.004) than those receiving other treatments. Median PFS and mOS from second-line starting were 8 and 28 months, without significant differences among various regimens. Pertuzumab-pretreated patients showed a mPFS and a mOS from second-line starting not significantly affected by type of second line, that is, T-DM1 or lapatinib/capecitabine ( p = 0.80 and p = 0.45, respectively). Conversely, pertuzumab-naïve patients receiving second-line T-DM1 showed a significantly higher mPFS compared with that of patients treated with lapatinib/capecitabine ( p = 0.004). Median OS from metastatic disease diagnosis was higher in patients treated with trastuzumab-based first line followed by second-line T-DM1 in comparison to pertuzumab-based first-line and second-line T-DM1 ( p = 0.003), although these data might be partially influenced by more favorable prognostic characteristics of patients in the pre-pertuzumab era . No significant differences emerged when comparing patients treated with ‘old’ or ‘new’ drugs ( p = 0.43), even though differences in the length of the follow-up between the two cohorts should be taken into account. Conclusion: Our results confirmed a relevant impact of first-line pertuzumab-based treatment and showed lower efficacy of second-line T-DM1 in trastuzumab/pertuzumab pretreated, as compared with pertuzumab-naïve patients. Our findings may help delineate a more appropriate therapeutic strategy in HER2-positive metastatic BC. Prospective randomized trials addressing this topic are awaited.
Published: 2021
Full Text: View/download PDF

18. The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial

Author: Pizzuti, Laura, Barba, Maddalena, Mazzotta, Marco, Krasniqi, Eriseld, Maugeri-Saccà, Marcello, Gamucci, Teresa, Berardi, Rossana, Livi, Lorenzo, Ficorella, Corrado, Natoli, Clara, Cortesi, Enrico, Generali, Daniele, La Verde, Nicla, Cassano, Alessandra, Bria, Emilio, Moscetti, Luca, Michelotti, Andrea, Adamo, Vincenzo, Zamagni, Claudio, Tonini, Giuseppe, Sergi, Domenico, Marinelli, Daniele, Paoletti, Giancarlo, Tomao, Silverio, Botticelli, Andrea, Marchetti, Paolo, Tinari, Nicola, Grassadonia, Antonino, Valerio, Maria Rosaria, Mirabelli, Rosanna, Fabbri, Maria Agnese, D’Ostilio, Nicola, Veltri, Enzo, Corsi, Domenico, Garrone, Ornella, Paris, Ida, Sarobba, Giuseppina, Meattini, Icro, Pistelli, Mirco, Giotta, Francesco, Lorusso, Vito, Garufi, Carlo, Russo, Antonio, Cazzaniga, Marina, Del Medico, Pietro, Roselli, Mario, Vaccaro, Angela, Perracchio, Letizia, di Benedetto, Anna, Daralioti, Theodora, Sperduti, Isabella, De Maria, Ruggero, Di Leo, Angelo, Sanguineti, Giuseppe, Ciliberto, Gennaro, and Vici, Patrizia
Published: 2021
Full Text: View/download PDF

19. PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy

Author: Cognetti, Francesco, Masetti, Riccardo, Fabi, Alessandra, Bianchi, Giulia, Santini, Donatella, Rognone, Alessia, Catania, Giovanna, Angelucci, Domenico, Naso, Giuseppe, Giuliano, Mario, Vassalli, Lucia, Vici, Patrizia, Scognamiglio, Giovanni, Generali, Daniele, Zambelli, Alberto, Colleoni, Marco, Tinterri, Corrado, Scanzi, Francesco, Vigna, Leonardo, Scavina, Paola, Gamucci, Teresa, Marrazzo, Emilia, Scinto, Angelo Fedele, Berardi, Rossana, Fabbri, Maria Agnese, Pinotti, Graziella, Franco, Daniela, Terribile, Daniela Andreina, Tonini, Giuseppe, Cianniello, Daniela, and Barni, Sandro
Published: 2021
Full Text: View/download PDF

20. Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer

Author: Puglisi, Fabio, Gerratana, Lorenzo, Lambertini, Matteo, Ceppi, Marcello, Boni, Luca, Montemurro, Filippo, Russo, Stefania, Bighin, Claudia, De Laurentiis, Michelino, Giuliano, Mario, Bisagni, Giancarlo, Durando, Antonio, Turletti, Anna, Garrone, Ornella, Ardizzoni, Andrea, Gamucci, Teresa, Colantuoni, Giuseppe, Gravina, Adriano, De Placido, Sabino, Cognetti, Francesco, and Del Mastro, Lucia
Published: 2021
Full Text: View/download PDF

21. MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study

Author: Krasniqi, E., Sacconi, A., Marinelli, D., Pizzuti, L., Mazzotta, M., Sergi, D., Capomolla, E., Donzelli, S., Carosi, M., Bagnato, A., Gamucci, T., Tomao, S., Natoli, C., Marchetti, P., Grassadonia, A., Tinari, N., De Tursi, M., Vizza, E., Ciliberto, G., Landi, L., Cappuzzo, F., Barba, M., Blandino, G., and Vici, P.
Published: 2021
Full Text: View/download PDF

22. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients

Author: Graziano, Vincenzo, Grassadonia, Antonino, Iezzi, Laura, Vici, Patrizia, Pizzuti, Laura, Barba, Maddalena, Quinzii, Alberto, Camplese, Annarita, Di Marino, Pietro, Peri, Marta, Veschi, Serena, Alberti, Saverio, Gamucci, Teresa, Di Gioacchino, Mario, De Tursi, Michele, Natoli, Clara, and Tinari, Nicola
Published: 2019
Full Text: View/download PDF

23. Evidence of inter-layer interaction in magneto-luminescence spectra of electron bilayers

Author: Aliaj, Ilirjan, Pellegrini, Vittorio, Gamucci, Andrea, Karmakar, Biswajit, Pinczuk, Aron, Pfeiffer, Loren N., and West, Ken W.
Subjects: Condensed Matter - Mesoscale and Nanoscale Physics
Abstract: Magneto-luminescence studies in electron bilayers reveal the hallmarks of the even-denominator and other quantum Hall states in the intensities and energies of the inter-band optical recombination lines. In the presence of a small tunneling gap between the layers the magneto-optical emission from the lowest anti-symmetric subband, not populated in a single-electron picture, displays maxima at filling factors 1 and 2/3. These findings uncover a loss of pseudospin polarization, where the pseudospin describes the layer index degree of freedom, that is linked to an anomalous population of the anti-symmetric level due to excitonic correlations. The results demonstrate a new realm to probe the impact of inter-layer Coulomb interaction in quantum Hall bilayers.
Published: 2012
Full Text: View/download PDF

24. Probing the spin states of three interacting electrons in quantum dots

Author: Gamucci, Andrea, Pellegrini, Vittorio, Singha, Achintya, Pinczuk, Aron, Pfeiffer, Loren N., West, Kenneth W., and Rontani, Massimo
Subjects: Condensed Matter - Mesoscale and Nanoscale Physics
Abstract: We observe a low-lying sharp spin mode of three interacting electrons in an array of nanofabricated AlGaAs/GaAs quantum dots by means of resonant inelastic light scattering. The finding is enabled by a suppression of the inhomogeneous contribution to the excitation spectra obtained by reducing the number of optically-probed quantum dots. Supported by configuration-interaction calculations we argue that the observed spin mode offers a direct probe of Stoner ferromagnetism in the simplest case of three interacting spin one-half fermions.
Published: 2011
Full Text: View/download PDF

25. Multi-GeV Electron Spectrometer

Author: Faccini, R., Anelli, F., Bacci, A., Batani, D., Bellaveglia, M., Benocci, R., Benedetti, C., Cacciotti, L., Cecchetti, C. A., Clozza, A., Cultrera, L., Di~Pirro, G., Drenska, N., Ferrario, M., Filippetto, D., Fioravanti, S., Gallo, A., Gamucci, A., Gatti, G., Ghigo, A., Giulietti, A., Giulietti, D., Gizzi, L. A., Koester, P., Labate, L., Levato, T., Lollo, V., Londrillo, P., Martellotti, S., Pace, E., Patack, N., Rossi, A., Tani, F., Serafini, L., Turchetti, G., Vaccarezza, C., and Valente, P.
Subjects: Physics - Instrumentation and Detectors, High Energy Physics - Experiment
Abstract: The advance in laser plasma acceleration techniques pushes the regime of the resulting accelerated particles to higher energies and intensities. In particular the upcoming experiments with the FLAME laser at LNF will enter the GeV regime with almost 1pC of electrons. From the current status of understanding of the acceleration mechanism, relatively large angular and energy spreads are expected. There is therefore the need to develop a device capable to measure the energy of electrons over three orders of magnitude (few MeV to few GeV) under still unknown angular divergences. Within the PlasmonX experiment at LNF a spectrometer is being constructed to perform these measurements. It is made of an electro-magnet and a screen made of scintillating fibers for the measurement of the trajectories of the particles. The large range of operation, the huge number of particles and the need to focus the divergence present unprecedented challenges in the design and construction of such a device. We will present the design considerations for this spectrometer and the first results from a prototype., Comment: 7 pages, 6 figures, submitted to NIM A
Published: 2010
Full Text: View/download PDF

26. Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study

Author: Cazzaniga, Marina Elena, primary, Pronzato, Paolo, additional, Amoroso, Domenico, additional, Bernardo, Antonio, additional, Biganzoli, Laura, additional, Bisagni, Giancarlo, additional, Blasi, Livio, additional, Bria, Emilio, additional, Cognetti, Francesco, additional, Crinò, Lucio, additional, De Laurentiis, Michelino, additional, Del Mastro, Lucia, additional, De Placido, Sabino, additional, Beano, Alessandra, additional, Ferraù, Francesco, additional, Foladore, Silva, additional, Forcignanò, Rosachiara, additional, Gamucci, Teresa, additional, Garrone, Ornella, additional, Gennari, Alessandra, additional, Giordano, Monica, additional, Giotta, Francesco, additional, Giovanardi, Filippo, additional, Latini, Luciano, additional, Livi, Lorenzo, additional, Marchetti, Paolo, additional, Mattioli, Rodolfo, additional, Michelotti, Andrea, additional, Montemurro, Filippo, additional, Putzu, Carlo, additional, Riccardi, Ferdinando, additional, Ricciardi, Giuseppina, additional, Romagnoli, Emanuela, additional, Sarobba, Giuseppina, additional, Spazzapan, Simon, additional, Tagliaferri, Pierosandro, additional, Tinari, Nicola, additional, Tonini, Giuseppe, additional, Turletti, Anna, additional, Verusio, Claudio, additional, Zambelli, Alberto, additional, and Mustacchi, Giorgio, additional
Published: 2023
Full Text: View/download PDF

27. Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives

Author: E. Krasniqi, G. Barchiesi, L. Pizzuti, M. Mazzotta, A. Venuti, M. Maugeri-Saccà, G. Sanguineti, G. Massimiani, D. Sergi, S. Carpano, P. Marchetti, S. Tomao, T. Gamucci, R. De Maria, F. Tomao, C. Natoli, N. Tinari, G. Ciliberto, M. Barba, and P. Vici
Subjects: Metastatic, Early, Breast cancer, Immunotherapy, Vaccine, HER2+, Diseases of the blood and blood-forming organs, RC633-647.5, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract: Abstract Breast cancer (BC) is a complex disease with primary or acquired incurability characteristics in a significant part of patients. Immunotherapeutical agents represent an emerging option for breast cancer treatment, including the human epidermal growth factor 2 positive (HER2+) subtype. The immune system holds the ability to spontaneously implement a defensive response against HER2+ BC cells through complex mechanisms which can be exploited to modulate this response for obtaining a clinical benefit. Initial immune system modulating strategies consisted mostly in vaccine therapies, which are still being investigated and improved. However, the entrance of trastuzumab into the scenery of HER2+ BC treatment was the real game changing event, which embodied a dominant immune-mediated mechanism. More recently, the advent of the immune checkpoint inhibitors has caused a new paradigm shift for immuno-oncology, with promising initial results also for HER2+ BC. Breast cancer has been traditionally considered poorly immunogenic, being characterized by relatively low tumor mutation burden (TMB). Nevertheless, recent evidence has revealed high tumor infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in a considerable proportion of HER2+ BC patients. This may translate into a higher potential to elicit anti-cancer response and, therefore, wider possibilities for the use and implementation of immunotherapy in this subset of BC patients. We are herein presenting and critically discussing the most representative evidence concerning immunotherapy in HER2+ BC cancer, both singularly and in combination with therapeutic agents acting throughout HER2-block, immune checkpoint inhibition and anti-cancer vaccines. The reader will be also provided with hints concerning potential future projection of the most promising immutherapeutic agents and approaches for the disease of interest.
Published: 2019
Full Text: View/download PDF

28. Use of nivolumab in elderly patients with advanced squamous non–small-cell lung cancer: results from the Italian cohort of an expanded access programme

Author: Grossi, Francesco, Crinò, Lucio, Logroscino, Antonio, Canova, Stefania, Delmonte, Angelo, Melotti, Barbara, Proto, Claudia, Gelibter, Alain, Cappuzzo, Federico, Turci, Daniele, Gamucci, Teresa, Antonelli, Paola, Marchetti, Paolo, Santoro, Armando, Giusti, Sabrina, Di Costanzo, Francesco, Giustini, Lucio, Del Conte, Alessandro, Livi, Lorenzo, Giannarelli, Diana, and de Marinis, Filippo
Published: 2018
Full Text: View/download PDF

29. Systematic vs. on-demand early palliative care in gastric cancer patients: a randomized clinical trial assessing patient and healthcare service outcomes

Author: Scarpi, Emanuela, Dall’Agata, Monia, Zagonel, Vittorina, Gamucci, Teresa, Bertè, Raffaella, Sansoni, Elisabetta, Amaducci, Elena, Broglia, Chiara Maria, Alquati, Sara, Garetto, Ferdinando, Schiavon, Stefania, Quadrini, Silvia, Orlandi, Elena, Casadei Gardini, Andrea, Ruscelli, Silvia, Ferrari, Daris, Pino, Maria Simona, Bortolussi, Roberto, Negri, Federica, Stragliotto, Silvia, Narducci, Filomena, Valgiusti, Martina, Farolfi, Alberto, Nanni, Oriana, Rossi, Romina, Maltoni, Marco, and on behalf of the Early Palliative Care Italian Study Group (EPCISG)
Published: 2019
Full Text: View/download PDF

30. A Preliminary Study on the Use of HD-sEMG for the Functional Imaging of Equine Superficial Muscle Activation during Dynamic Mobilization Exercises

Author: Fiorenza Gamucci, Marcello Pallante, Sybille Molle, Enrico Merlo, and Andrea Bertuglia
Subjects: electromyography, objective outcome measurement, dynamic mobilization exercises, rehabilitation, horses, Veterinary medicine, SF600-1100, Zoology, QL1-991
Abstract: Superficial skeletal muscle activation is associated with an electric activity. Bidimensional High-Density Surface Electromyography (HD-sEMG) is a non-invasive technique that uses a grid of equally spaced electrodes applied on the skin surface to detect and portray superficial skeletal muscle activation. The goal of the study was to evaluate the feasibility of HD-sEMG to detect electrical activation of skeletal muscle and its application during rehabilitation exercises in horses. To fulfil this aim, activation of the superficial descending pectoral and external abdominal oblique core muscles were measured using HD-sEMG technology during dynamic mobilization exercises to induce lateral bending and flexion/extension tasks of the trunk. Masseter muscle was instrumented during mastication as a control condition. A 64 surface EMG channel wireless system was used with a single 64 electrode grid or a pair of 32 electrode grids. HD-sEMG provided unique information on the muscular activation onset, duration, and offset, along each motor task, and permitting inferences about the motor control strategy actuated by the central nervous system. Signals were further processed to obtain firing frequencies of few motor-neurons. Estimation of electromyographic amplitude and spectral parameters allowed detecting the onset of muscular fatigue during the motor tasks performed. HD-sEMG allows the assessment of muscular activation in horses performing specific motor tasks, supporting its future application in clinical and research settings.
Published: 2022
Full Text: View/download PDF

31. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

Author: Koroveshi, Dhurata, Bouzid, Kamel, Casalnuovo, Monica, Cascallar, Diana, Korbenfeld, Ernesto Pablo, Bastick, Patricia, Beith, Jane, Colosimo, Maree, Friedlander, Michael, Ganju, Vinod, Green, Michael, Patterson, Kevin, Redfern, Andrew, Richardson, Gary, Ceric, Timur, Gordana, Kecman, Beato, Carlos Augusto, Ferrari, Marcela, Hegg, Roberto, Helena, Vanessa, Ismael, Gustavo Fernando, Lessa, Alvaro Edson, Mano, Max, Morelle, Alessandra, Nogueira, Jose Alberto, Timcheva, Konstanta, Tomova, Antoaneta, Tsakova, Maya, Zlatareva-Petrova, Ani, Asselah, Jamil, Assi, Hazem, Brezden-Masley, Christine, Chia, Stephen, Freedman, Ori, Harb, Mohammed, Joy, Anil Abraham, Kulkarni, Swati, Prady, Catherine, Gaete, Alejandro Andres Acevedo, Matamala, Luis, Torres, Roberto, Yanez, Eduardo, Franco, Sandra, Urrego, Marcela, Gugić, Damir, Vrbanec, Damir, Melichar, Bohuslav, Prausová, Jana, Vyzula, Rostislav, Pilarte, Rafael Gutierrez, León, María Isabel, Muñoz, Rene, Ramos, Glenda, Azeem, Hamdy Abdel, Aziz, Amr Abdel, El Zawahry, Heba, Osegueda, Finlander Rosales, Alexandre, Jerome, Artignan, Xavier, Barletta, Hugues, Beguier, Emmanuel, Berdah, Jean-François, Marty, Chantal Bernard, Bollet, Marc, Bourgeois, Hugues, Bressac, Claude, Burki, Franck, Campone, Mario, Coeffic, David, Cojocarasu, Oana Zveltlana, Dagada, Corinne, Dalenc, Florence, Del Piano, Francesco, Desauw, Christophe, Desmoulins, Isabelle, Dohollou, Nadine, Egreteau, Joelle, Ferrero, Jean-Marc, Foa, Cyril, Garidi, Reda, Gasnault, Laurent, Gligorov, Joseph, Guardiola, Emmanuel, Hamizi, Salima, Jarcau, Rosana, Jacquin, Jean-Philippe, Jaubert, Dominique, Jolimoy, Geneviève, Mineur, Hortense Laharie, Largillier, Remy, Leduc, Bernard, Martin, Philippe, Melis, Adrien, Monge, Jeremy, Moullet, Isabelle, Mousseau, Mireille, Nguyen, Suzanne, Orfeuvre, Hubert, Petit, Thierry, Pivot, Xavier, Priou, Frank, Bach, Isabelle Sillet, Simon, Helene, Stefani, Laetitia, Uwer, Lionel, Youssef, Ali, Aktas, Bahriye, von der Assen, Albert, Augustin, Doris, Balser, Christina, Bauer, Lelia-Eveline, Bechtner, Christina, Beyer, Greta, Brucker, Cosima, Bückner, Ute, Busch, Steffi, Christensen, Bernd, Deryal, Mustafa, Farrokh, Andre, Faust, Elke, Friedrichs, Kay, Graf, Heiko, Griesshammer, Martin, Grischke, Eva-Maria, Hänle, Claudia, Heider, Andrea, Henschen, Stephan, Hesse, Tobias, Jackisch, Christian, Kisro, Jens, Köhler, Andreas, Kuemmel, Sherko, Lampe, Dieter, Lantzsch, Tilmann, Latos, Kunibert, Lex, Benno, Liedtke, Cornelia, Luedders, Doerte, Maintz, Christoph, Müller, Volkmar, Overkamp, Friedrich, Park-Simon, Tjoung-won, Paul, Marion, Prechtl, Anita, Ringsdorf, Uta, Runnebaum, Ingo, Ruth, Sylvia, Salat, Christoph, Scheffen, Iris, Schilling, Jörg, Schmatloch, Sabine, Schmidt, Marcus, Schneeweiss, Andreas, Schrader, Iris, Seipelt, Gernot, Simon, Elke, Stefek, Andrea, Stickeler, Elmar, Thill, Marc, Tio, Joke, Tuczek, Anna, Warm, Mathias, Weigel, Michael, Wischnik, Arthur, Wojcinski, Sebastian, Ziegler-Löhr, Katja, Aravantinos, Gerasimos, Ardavanis, Alexandros, Fountzilas, George, Gogas, Helen, Kakolyris, Stylianos, Mavroudis, Dimitris, Papadimitriou, Christos, Papandreou, Christos, Papazisis, Konstantinos, Castro, Hugo, Hernandez-Monroy, Cesar Estuardo, Ngan, Roger, Yeo, Winnie, Bittner, Nora, Boer, Katalin, Csejtei, Andras, Horvath, Zsolt, Kocsis, Judit, Mangel, László Csaba, Mezei, Klara, Nagy, Zsuzsanna, Szanto, Janos, Atmakusuma, Djumhana, Fadjari, Heri, Kurnianda, Djohan, Prayogo, Nugroho, Tanggo, Eddie Herman, Coate, Linda, Hennessy, Bryan, Kelly, Cathy, Martin, Michael, Nasim, Saira, O'Connor, Miriam, Aieta, Michele, Allegrini, Giacomo, Amadori, Dino, Bidoli, Paolo, Biti, Giampaolo, Bordonaro, Roberto, Bottini, Alberto, Carterni, Giacomo, Cavanna, Luigi, Cazzaniga, Marina, Cognetti, Francesco, Contu, Antonio, Cruciani, Giorgio, Donadio, Michela, Falcone, Alfredo, Farci, Daniele, Forcignanò, R. Chiara, Frassoldati, Antonio, Gaion, Fernando, Gamucci, Teresa, Giotta, Francesco, de Laurentiis, Michele, Livi, Lorenzo, Lorusso, Vito, Maiello, Evaristo, Marchetti, Paolo, Mariani, Gabriella, Mion, Marta, Moscetti, Luca, Musolino, Antonino, Pazzola, Antonio, Pedrazzoli, Paolo, Pigi, Andrea, de Placido, Sabino, Caremoli, Elena Rota, Santoro, Armando, Tienghi, Amelia, Ahn, Jin-Seok, Jung, Kyung Hae, Lee, Keun Seok, Lee, Soo Hyeon, Seo, Jae Hong, Sohn, Joo-Hyuk, Cesas, Alvydas, Juozaityte, Elona, Cheah, Nellie Lay Chin, Chong, Flora Li Tze, Devi, Beena C.R., Phua, Vincent, Teoh, Darren, Ching, Lee Wei, Yusof, Mastura, Corona, Jorge, Dominguez, Adriana, Mendoza, René Lazaro González, Hernandez, Carlos Alberto, Ramiro, Alejandro Juarez, Santos, Juan Matos, Espinosa, Paola Morales, Villarreal Garza, Cynthia Mayte, Errihani, Hassan, Bakker, Sandra, van den Berkmortel, Franchette, Blaisse, R.J.B., Huinink, Daan ten Bokkel, van den Bosch, J., Braun, J.J., Dercksen, M.W., Droogendijk, Helga, Erdkamp, Frans, Haringhuizen, Annebeth, de Jongh, F.E., Kok, T.C., Los, Maartje, Madretsma, Stanley, Terwogt, Jetske M. Meerum, van der Padt, Annemieke, van Rossum-Schornagel, Quirine Clementine, Smilde, T.J., de Valk, Bart, van der Velden, Annette, van Warmerdam, Laurence, van de Wouw, A.J., North, Richard, Kersten, Christian, Mjaaland, Ingvild, Wist, Erik, Aziz, Zeba, Masood, Nehal, Rashid, Kamran, Shah, Mazhar, Alcedo, Juan Carlos, Aleman, Diana, Neciosup, Silvia, Reategui, Rocio, Valdiviezo, Natalia, Vera, Luis, Fernando, Gracieux, Roque, Fernando, Strebel, Heinrik Martin, Krzemieniecki, Krzysztof, Litwiniuk, Maria, Mruk, Andrzej, Pienkowski, Tadeusz, Sawrycki, Piotr, Slomian, Grzegorz, Tomczak, Piotr, Afonso, Noemia, Cardoso, Fátima, Damasceno, Margarida, Nave, Monica, Badulescu, Florinel, Ciule, Larisa, Curescu, Stefan, Eniu, Alexandru, Filip, Dumitru, Grecea, Daniela, Jinga, Dan-Corneliu, Lungulescu, Dan, Oprean, Cristina Marinela, Stanculeanu, Dana Lucia, Turdean, Maria, Dvornichenko, Viktoria, Emelyanov, Sergey, Lichinitser, Mikhail, Manikhas, Alexey, Sakaeva, Dina, Shirinkin, Vadim, Stroyakovskiy, Daniil, Abulkhair, Omalkhair, Zekri, Jamal, Filipovic, Sladjana, Kovcin, Vladimir, Nedovic, Jasmina, Pesic, Jasna, Vasovic, Suzana, Ng, Raymond, Bystricky, Branislav, Leskova, Jaroslava, Mardiak, Jozef, Mišurová, Etela, Wagnerova, Maria, Takač, Iztok, Demetriou, Georgia Savva, Dreosti, Lydia, Govender, Poovandren, Jordaan, Johannes Petrus, Veersamy, Petrosian, Romero, Jose Luis Alonso, Lopez, Norberto Batista, Arias, Carmen Cañabate, Chacon, Jose, Aramburo, Antonio Fernandez, Morales, Luis Antonio Fernandez, Garcia, Mirta, Estevez, Laura Garcia, Garcia-Palomo Perez, Andres, Garcia Saenz, Jose Angel, Garcia Sanchis, Laura, Cubells, Laia Garrigos, Cortijo, Lucia Gonzalez, Santiago, Santiago Gonzalez, De Aranguiz, Blanca Hernando Fernandez, Mañas, José Juan Illarramendi, Gallego, Pedro Jimenez, Cussac, Antonio Llombart, Ferrandiz, Cristina Llorca, Garrido, Maria Lomas, Alvarez, Pilar Lopez, Vega, Jose Manuel Lopez, Del Prado, Purificacion Martinez, Jañez, Noelia Martinez, Murillo, Serafin Morales, Rosales, Adolfo Murias, Jaso, Laura Murillo, Fernandez, Ignacio Pelaez, Martorell, Antonia Perello, Carrion, Ramon Perez, Simon, Sonia Pernas, Alcibar, Arrate Plazaola, Lorenzo, Jose Ponce, Garcia, Vanesa Quiroga, Asensio, Teresa Ramon y Cajal, Maicas, Maria Dolores Torregrosa, Villanueva Silva, Maria Jose, Killander, Fredrika, Svensson, Jan Henry, Fehr, Mathias, Hauser, Nik, Müller, Andreas, Pagani, Olivia, Passmann-Kegel, Heike, Popescu, Razvan, Rabaglio, Manuela, Rauch, Daniel, Schlatter, Christina, Zaman, Khalil, Chang, Tsai-Wang, Huang, Chiun-Sheng, Wang, Hwei-Chung, Yu, Jyh-Cherng, Bandidwattanawong, Chanyoot, Maneechavakajorn, Jedzada, Seetalarom, Kasan, Dejthevaporn, Thitiya (Sirisinha), Somwangprasert, Areewan, Vongsaisuwon, Mawin, Akbulut, Hakan, Altundag, Kadri, Arican, Ali, Bozcuk, Hakan, Eralp, Yesim, Idris, Mohamed, Isikdogan, Abdurrahman, Senol, Coskun Hasan, Sevinc, Alper, Uygun, Kazim, Yucel, Eftal, Yucel, Idris, Yumuk, Fulden, Shparyk, Yaroslav, Voitko, Nataliia, Jaloudi, Mohammed, Adams, Jocelyn, Agrawal, Rajiv, Ahmed, Samreen, Alhasso, Abdulla, Allerton, Rozenn, Anwar, Suhail, Archer, Caroline, Ashford, Richard, Barraclough, Lisa, Bertelli, Gianfilippo, Bishop, Jill, Branson, Tony, Butt, Mohammed, Chakrabarti, Amit, Chakraborti, Prabir, Churn, Mark, Crowley, Clare, Davis, Ruth, Dhadda, Amandeep, Eldeeb, Hany, Fraser, Judith, Hall, Julia, Hickish, Tamas, Hogg, Martin, Howe, Theresa, Joffe, Jonathan, Kelleher, Muireann, Kelly, Stephen, Kendall, Anne, Kristeleit, Hartmut, Lumsden, Graeme, Macmillan, Craig, MacPherson, Iain, Malik, Zafar, Mithal, Natasha, Neal, Anthony, Panwar, Udaiveer, Proctor, Andrew, Proctor, Steven John, Raj, Sanjay, Rehman, Shazza, Sandri, Ines, Scatchard, Kate, Sherwin, Elizabeth, Sims, Eliot, Singer, Julian, Smith, Sarah, Tahir, Saad, Taylor, Wendy, Tsalic, Medy, Verrill, Mark, Wardley, Andrew, Waters, Simon, Wheatley, Duncan, Wright, Kathryn, Yuille, Frances, Alonso, Isabel, Artagaveytia, Nora, Rodriguez, Robinson, Arbona, Esther, Garcia, Yuraima, Lion, Lorena, Marcano, Dalila, Van Thuan, Tran, Gligorov, J., Ataseven, B., Verrill, M., De Laurentiis, M., Jung, K.H., Azim, H.A., Al-Sakaff, N., Lauer, S., Shing, M., and Pivot, X.
Published: 2017
Full Text: View/download PDF

32. Long-term outcome of breast cancer patients with pathologic N3a lymph node stage

Author: Grassadonia, Antonino, Vici, Patrizia, Gamucci, Teresa, Moscetti, Luca, Pizzuti, Laura, Mentuccia, Lucia, Iezzi, Laura, Scognamiglio, Maria Teresa, Zilli, Marinella, Giampietro, Jamara, Graziano, Vincenzo, Natoli, Clara, and Tinari, Nicola
Published: 2017
Full Text: View/download PDF

33. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

Author: Bon, Giulia, Pizzuti, Laura, Laquintana, Valentina, Loria, Rossella, Porru, Manuela, Marchiò, Caterina, Krasniqi, Eriseld, Barba, Maddalena, Maugeri-Saccà, Marcello, Gamucci, Teresa, Berardi, Rossana, Livi, Lorenzo, Ficorella, Corrado, Natoli, Clara, Cortesi, Enrico, Generali, Daniele, La Verde, Nicla, Cassano, Alessandra, Bria, Emilio, Moscetti, Luca, Michelotti, Andrea, Adamo, Vincenzo, Zamagni, Claudio, Tonini, Giuseppe, Barchiesi, Giacomo, Mazzotta, Marco, Marinelli, Daniele, Tomao, Silverio, Marchetti, Paolo, Valerio, Maria Rosaria, Mirabelli, Rosanna, Russo, Antonio, Fabbri, Maria Agnese, D’Ostilio, Nicola, Veltri, Enzo, Corsi, Domenico, Garrone, Ornella, Paris, Ida, Sarobba, Giuseppina, Giotta, Francesco, Garufi, Carlo, Cazzaniga, Marina, Del Medico, Pietro, Roselli, Mario, Sanguineti, Giuseppe, Sperduti, Isabella, Sapino, Anna, De Maria, Ruggero, Leonetti, Carlo, Di Leo, Angelo, Ciliberto, Gennaro, Falcioni, Rita, and Vici, Patrizia
Published: 2020
Full Text: View/download PDF

34. Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study.

Author: Cazzaniga, Marina Elena, Pronzato, Paolo, Amoroso, Domenico, Bernardo, Antonio, Biganzoli, Laura, Bisagni, Giancarlo, Blasi, Livio, Bria, Emilio, Cognetti, Francesco, Crinò, Lucio, De Laurentiis, Michelino, Del Mastro, Lucia, De Placido, Sabino, Beano, Alessandra, Ferraù, Francesco, Foladore, Silva, Forcignanò, Rosachiara, Gamucci, Teresa, Garrone, Ornella, and Gennari, Alessandra
Subjects: CONFIDENCE intervals, ONCOGENES, METASTASIS, ANTINEOPLASTIC agents, HYDROCARBONS, TREATMENT effectiveness, DESCRIPTIVE statistics, RESEARCH funding, CELL lines, BEVACIZUMAB, ODDS ratio, PROGRESSION-free survival, BREAST tumors, LONGITUDINAL method, OVERALL survival, EVALUATION
Abstract: Simple Summary: Breast cancer is one of the most common oncological diseases among women in Western Countries and Italy as well. GIM 13-AMBRA is a patient journey study regarding how the prognosis of metastatic breast cancer patients has changed in the last decades as a result of the introduction of new drugs in clinical practice. This study also provides information regarding the different natural histories of breast cancer according to the presence or absence of hormone receptors and HER2 receptors. GIM 13-AMBRA is a longitudinal cohort study aimed at describing therapeutic strategies and the relative outcome parameters in 939 HER2-ve MBC patients. Taxanes–based regimens, or taxanes + targeted agents, mainly Bevacizumab, were the preferred first choice in both Luminal (30.2%) and TNBC (33.3%) patients. The median PFS1 was 12.5 months (95% CI 16.79–19.64), without any significant difference according to subtypes, while the median Time to first Treatment Change (TTC1) was significantly lower in TNBC patients (7.7 months—95% CI 5.7–9.2) in comparison to Luminal A (13.2 months, 95% CI 11.7–15.1) and Luminal B patients (11.8 months, 95% CI 10.3–12.8). PFS2 was significantly shorter in TNBC patients (5.5 months, 95% CI 4.3–6.5 vs. Luminal A—9.4, 95% CI 8.1–10.7, and Luminal B—7.7 95% CI 6.8–8.2, F-Ratio 4.30, p = 0.014). TTC2 was significantly lower in patients with TNBC than in those with the other two subtypes. The median OS1 was 35.2 months (95% CI 30.8–37.4) for Luminal A patients, which was significantly higher than that for both Luminal B (28.9 months, 95% CI 26.2–31.2) and TNBC (18.5 months, 95% CI 16–20.1, F-ratio 7.44, p = 0.0006). The GIM 13—AMBRA study is one of the largest collections ever published in Italy and provides useful results in terms of time outcomes for first, second, and further lines of treatment in HER2- MBC patients. [ABSTRACT FROM AUTHOR]
Published: 2024
Full Text: View/download PDF

35. Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study

Author: Fabbri, Agnese, primary, Nelli, Fabrizio, additional, Botticelli, Andrea, additional, Giannarelli, Diana, additional, Marrucci, Eleonora, additional, Fiore, Cristina, additional, Virtuoso, Antonella, additional, Scagnoli, Simone, additional, Pisegna, Simona, additional, Alesini, Daniele, additional, Sini, Valentina, additional, Orlandi, Armando, additional, Fabi, Alessandra, additional, Piacentini, Federico, additional, Moscetti, Luca, additional, D’Auria, Giuliana, additional, Gamucci, Teresa, additional, Mazzotta, Marco, additional, Pizzuti, Laura, additional, Vici, Patrizia, additional, Cretella, Elisabetta, additional, Scavina, Paola, additional, La Cesa, Annalisa, additional, Persano, Mara, additional, Atzori, Francesco, additional, and Ruggeri, Enzo Maria, additional
Published: 2023
Full Text: View/download PDF

36. Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study

Author: Di Lisa, Francesca Sofia, primary, Krasniqi, Eriseld, additional, Pizzuti, Laura, additional, Barba, Maddalena, additional, Cannita, Katia, additional, De Giorgi, Ugo, additional, Borella, Fulvio, additional, Foglietta, Jennifer, additional, Cariello, Anna, additional, Ferro, Antonella, additional, Picardo, Elisa, additional, Mitidieri, Marco, additional, Sini, Valentina, additional, Stani, Simonetta, additional, Tonini, Giuseppe, additional, Santini, Daniele, additional, La Verde, Nicla, additional, Gambaro, Anna Rita, additional, Grassadonia, Antonino, additional, Tinari, Nicola, additional, Garrone, Ornella, additional, Sarobba, Giuseppina, additional, Livi, Lorenzo, additional, Meattini, Icro, additional, D’Auria, Giuliana, additional, Vergati, Matteo, additional, Gamucci, Teresa, additional, Pistelli, Mirco, additional, Berardi, Rossana, additional, Risi, Emanuela, additional, Giotta, Francesco, additional, Lorusso, Vito, additional, Rinaldi, Lucia, additional, Artale, Salvatore, additional, Cazzaniga, Marina Elena, additional, Zustovich, Fable, additional, Cappuzzo, Federico, additional, Landi, Lorenza, additional, Torrisi, Rosalba, additional, Scagnoli, Simone, additional, Botticelli, Andrea, additional, Michelotti, Andrea, additional, Fratini, Beatrice, additional, Saltarelli, Rosa, additional, Paris, Ida, additional, Muratore, Margherita, additional, Cassano, Alessandra, additional, Gianni, Lorenzo, additional, Gaspari, Valeria, additional, Veltri, Enzo Maria, additional, Zoratto, Federica, additional, Fiorio, Elena, additional, Fabbri, Maria Agnese, additional, Mazzotta, Marco, additional, Ruggeri, Enzo Maria, additional, Pedersini, Rebecca, additional, Valerio, Maria Rosaria, additional, Filomeno, Lorena, additional, Minelli, Mauro, additional, Scavina, Paola, additional, Raffaele, Mimma, additional, Astone, Antonio, additional, De Vita, Roy, additional, Pozzi, Marcello, additional, Riccardi, Ferdinando, additional, Greco, Filippo, additional, Moscetti, Luca, additional, Giordano, Monica, additional, Maugeri-Saccà, Marcello, additional, Zennaro, Alessandro, additional, Botti, Claudio, additional, Pelle, Fabio, additional, Cappelli, Sonia, additional, Cavicchi, Flavia, additional, Vizza, Enrico, additional, Sanguineti, Giuseppe, additional, Tomao, Federica, additional, Cortesi, Enrico, additional, Marchetti, Paolo, additional, Tomao, Silverio, additional, Speranza, Iolanda, additional, Sperduti, Isabella, additional, Ciliberto, Gennaro, additional, and Vici, Patrizia, additional
Published: 2023
Full Text: View/download PDF

37. 209P Trastuzumab plus lapatinib or chemotherapy in patients with HER2-positive advanced breast cancer refractory to anti-HER2 therapies: A randomized, multicenter, phase II trial (GIM12-TYPHER)

Author: De Angelis, C., primary, Pagliuca, M., additional, Gamucci, T., additional, Mansutti, M., additional, Ballatore, Z., additional, De Laurentiis, M., additional, Bordonaro, R., additional, Pazzola, A., additional, Leonardi, V., additional, Bruzzese, D., additional, Mosconi, A.M., additional, Molica, C., additional, Cinieri, S., additional, Fabi, A., additional, Del Mastro, L., additional, Puglisi, F., additional, de Placido, S., additional, Giuliano, M., additional, and Arpino, G., additional
Published: 2023
Full Text: View/download PDF

38. [Untitled]

Author: Francesco S Mennini, Andrea Marcellusi, Chiara Bini, Maria Assunta Rotundo, Alessandro Giunta, Antonio Gasbarrini, Guido Valesini, Pier Luigi Canonico, Ettore Novellino, Valentina Orlando, Alessandra Mecozzi, Teresa Gamucci, Livio Pagano, Eugenio Di Brino, Matteo Ruggeri, and Americo Cicchetti
Subjects: Medical technology, R855-855.5
Published: 2019
Full Text: View/download PDF

39. Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life

Author: Farolfi, Alberto, Ruscelli, Silvia, Valgiusti, Martina, Pini, Sara, Faedi, Marina, Ragazzini, Angela, Pittureri, Cristina, Amaducci, Elena, Guglieri, Irene, Bergamo, Francesca, Lonardi, Sara, Di Nunzio, Camilla, Bosco, Monica, Bocci, Barbara, Bramanti, Alfina, Gandini, Chiara, Buonadonna, Angela, Comandone, Alessandro, Zoccali, Sonia, Pino, Maria Simona, Dalu, Davide, Sozzi, Pietro, Gozza, Alberto, Giordano, Monica, Longhi, Carla, Autelitano, Cristina, Gamucci, Teresa, Mastromauro, Cataldo, Scognamiglio, Rodolfo, Degiovanni, Daniela, Negri, Federica, Caraceni, Augusto, Montanari, Luigi, Maltoni, Marco, Scarpi, Emanuela, Dall’Agata, Monia, Schiavon, Stefania, Biasini, Claudia, Codecà, Carla, Broglia, Chiara Maria, Sansoni, Elisabetta, Bortolussi, Roberto, Garetto, Ferdinando, Fioretto, Luisa, Cattaneo, Maria Teresa, Giacobino, Alice, Luzzani, Massimo, Luchena, Giovanna, Alquati, Sara, Quadrini, Silvia, Zagonel, Vittorina, Cavanna, Luigi, Ferrari, Daris, Pedrazzoli, Paolo, Frassineti, Giovanni Luca, Galiano, Antonella, Casadei Gardini, Andrea, Monti, Manlio, and Nanni, Oriana
Published: 2016
Full Text: View/download PDF

40. Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience

Author: Moscetti, L., Vici, P., Gamucci, T., Natoli, C., Cortesi, E., Marchetti, P., Santini, D., Giuliani, R., Sperduti, I., Mauri, M., Pizzuti, L., Mancini, M.L., Fabbri, M.A., Magri, V., Iezzi, L., Sini, V., D'Onofrio, L., Mentuccia, L., Vaccaro, A., Ramponi, S., Roma, C.L., and Ruggeri, E.M.
Published: 2016
Full Text: View/download PDF

41. Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV ‘real life’ trial on the variability of response to opioids

Author: Monfredo, M., Mistretta, R., di Salemi, P.O., Zecca, E., Cartoni, C., Brunetti, G.A., Tassinari, D., Drudi, F., Rizzi, F., Pizzuto, M., Formaglio, F., Luzi, M., Narducci, F., Boscolo, G., Mangiapia, M., Artioli, F., Lazzari, M., Dauri, M., Diodati, M., Cupaiolo, A., Mameli, S., Preti, P., Ferrari, P., Vasini, G., Roy, M.T., Piva, L., Nardi, L.F., Montanari, L., Reina, V., Fusco, F., Orsi, L., Molinari, E., Corli, O., Floriani, I., Roberto, A., Montanari, M., Galli, F., Greco, M.T., Caraceni, A., Kaasa, S., Dragani, T.A., Azzarello, G., Luzzani, M., Cavanna, L., Bandieri, E., Gamucci, T., Lipari, G., Di Gregorio, R., Valenti, D., Reale, C., Pavesi, L., Iorno, V., Crispino, C., Pacchioni, M., and Apolone, G.
Published: 2016
Full Text: View/download PDF

42. Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial

Author: Lorusso, D., Scambia, G., Pignata, S., Sorio, R., Amadio, G., Lepori, S., Mosconi, A., Pisano, C., Mangili, G., Maltese, G., Sabbatini, R., Artioli, G., Gamucci, T., Di Napoli, M., Capoluongo, E., Ludovini, V., Raspagliesi, F., and Ferrandina, G.
Published: 2016
Full Text: View/download PDF

43. Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives

Author: Krasniqi, E., Barchiesi, G., Pizzuti, L., Mazzotta, M., Venuti, A., Maugeri-Saccà, M., Sanguineti, G., Massimiani, G., Sergi, D., Carpano, S., Marchetti, P., Tomao, S., Gamucci, T., De Maria, R., Tomao, F., Natoli, C., Tinari, N., Ciliberto, G., Barba, M., and Vici, P.
Published: 2019
Full Text: View/download PDF

44. Prognostic value of gender and primary tumor location in metastatic colon cancer

Author: Grassadonia, Antonino, primary, Carletti, Erminia, additional, De Luca, Antonella, additional, Vici, Patrizia, additional, Di Lisa, Francesca Sofia, additional, Filomeno, Lorena, additional, Cicero, Giuseppe, additional, De Lellis, Laura, additional, Veschi, Serena, additional, Florio, Rosalba, additional, Brocco, Davide, additional, Di Marino, Pietro, additional, Alberti, Saverio, additional, Gamucci, Teresa, additional, Borrelli, Paola, additional, Cama, Alessandro, additional, and Tinari, Nicola, additional
Published: 2023
Full Text: View/download PDF

45. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial

Author: Del Mastro, Lucia, De Placido, Sabino, Bruzzi, Paolo, De Laurentiis, Michele, Boni, Corrado, Cavazzini, Giovanna, Durando, Antonio, Turletti, Anna, Nisticò, Cecilia, Valle, Enrichetta, Garrone, Ornella, Puglisi, Fabio, Montemurro, Filippo, Barni, Sandro, Ardizzoni, Andrea, Gamucci, Teresa, Colantuoni, Giuseppe, Giuliano, Mario, Gravina, Adriano, Papaldo, Paola, Bighin, Claudia, Bisagni, Giancarlo, Forestieri, Valeria, and Cognetti, Francesco
Published: 2015
Full Text: View/download PDF

46. Identification of Subgroups of Early Breast Cancer Patients at High Risk of Nonadherence to Adjuvant Hormone Therapy: Results of an Italian Survey

Author: Tinari, Nicola, Fanizza, Caterina, Romero, Marilena, Gambale, Elisabetta, Moscetti, Luca, Vaccaro, Angela, Seminara, Patrizia, Longo, Flavia, Gori, Stefania, Vici, Patrizia, Gamucci, Teresa, Mauri, Mariella, Laudadio, Lucio, Nuzzo, Antonio, Fabbri, Maria Agnese, Fattoruso, Silvia Ileana, Mazzilli, Lorenzo, Grassadonia, Antonino, Cianchetti, Ettore, and Natoli, Clara
Published: 2015
Full Text: View/download PDF

47. Spray-coated few-layer graphene as an aluminium battery cathode

Author: Shaikshavali Petnikota, Daniel Koch, Muhammad Imran, Joka Buha, Jaya Kumar Panda, Mohammad Akbari Garakani, Luigi Marasco, Andrea Gamucci, Francesco Bonaccorso, and Vittorio Pellegrini
Subjects: Fuel Technology, Renewable Energy, Sustainability and the Environment, Energy Engineering and Power Technology
Abstract: We report herein wet-jet milling produced graphene (GWJM) as a high performing aluminium battery (AB) cathode material.
Published: 2022
Full Text: View/download PDF

48. Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial

Author: Daniele Santini, Marco Mazzotta, Antonio Giordano, Silverio Tomao, Andrea Michelotti, Giuseppe Tonini, Giuseppe Sanguineti, Corrado Ficorella, Teresa Gamucci, Filippo Greco, E. Capomolla, Maddalena Barba, Eriseld Krasniqi, Alice Villa, Enzo Veltri, Vito Lorusso, Francesco Giotta, Claudio Botti, Vittorio Gebbia, Laura Pizzuti, Katia Cannita, Paolo Marchetti, Maria Mauri, Elisabetta Anselmi, Patrizia Vici, Ida Paris, Isabella Sperduti, Luca Moscetti, Lorenzo Livi, Maria Rosaria Valerio, Gennaro Ciliberto, Icro Meattini, Federica Tomao, Krasniqi, Eriseld, Pizzuti, Laura, Valerio, Maria Rosaria, Capomolla, Elisabetta, Botti, Claudio, Sanguineti, Giuseppe, Marchetti, Paolo, Anselmi, Elisabetta, Tomao, Silverio, Giordano, Antonio, Ficorella, Corrado, Cannita, Katia, Livi, Lorenzo, Meattini, Icro, Mauri, Maria, Greco, Filippo, Veltri, Enzo Maria, Michelotti, Andrea, Moscetti, Luca, Giotta, Francesco, Lorusso, Vito, Paris, Ida, Tomao, Federica, Santini, Daniele, Tonini, Giuseppe, Villa, Alice, Gebbia, Vittorio, Gamucci, Teresa, Ciliberto, Gennaro, Sperduti, Isabella, Mazzotta, Marco, Barba, Maddalena, and Vici, Patrizia
Subjects: Adult, Oncology, Eribulin Mesylate, medicine.medical_specialty, eribulin mesylate, medicine.medical_treatment, Triple Negative Breast Neoplasms, chemotherapy, triple negative metastatic breast cancer, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, adjuvant, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, 80 and over, medicine, Humans, Chemotherapy, Efficacy outcomes, Eribulin mesylate, Toxicity outcomes, Triple negative metastatic breast cancer, Progression-free survival, Furans, Adverse effect, Triple-negative breast cancer, Aged, Neoplasm Staging, Retrospective Studies, Aged, 80 and over, business.industry, Retrospective cohort study, General Medicine, Ketones, Middle Aged, medicine.disease, Metastatic breast cancer, Neoadjuvant Therapy, Progression-Free Survival, chemistry, Chemotherapy, Adjuvant, Female, 030211 gastroenterology & hepatology, toxicity outcomes, efficacy outcomes, adult, aged, antineoplastic combined chemotherapy protocols, female, furans, humans, ketones, middle aged, neoadjuvant therapy, neoplasm staging, progression-free survival, retrospective studies, triple negative breast neoplasms, business, Research Paper, Eribulin
Abstract: Introduction: Large and consistent evidence supports the use of eribulin mesylate in clinical practice in third or later line treatment of metastatic triple negative breast cancer (mTNBC). Conversely, there is paucity of data on eribulin efficacy in second line treatment. Methods: We investigated outcomes of 44 mTNBC patients treated from 2013 through 2019 with second line eribulin mesylate in a multicentre retrospective study involving 14 Italian oncologic centres. Results: Median age was 51 years, with 11.4% of these patients being metastatic at diagnosis. Median overall survival (OS) and progression free survival (PFS) from eribulin starting were 11.9 (95%CI: 8.4-15.5) and 3.5 months (95%CI: 1.7-5.3), respectively. We observed 8 (18.2%) partial responses and 10 (22.7%) patients had stable disease as best response. A longer PFS on previous first line treatment predicted a better OS (HR=0.87, 95%CI: 0.77-0.99, p= 0.038) and a longer PFS on eribulin treatment (HR=0.92, 95%CI: 0.85-0.98, p=0.018). Progression free survival to eribulin was also favorably influenced by prior adjuvant chemotherapy (HR=0.44, 95%CI: 0.22-0.88, p=0.02). Eribulin was generally well tolerated, with grade 3-4 adverse events being recorded in 15.9% of patients. Conclusions: The outcomes described for our cohort are consistent with those reported in the pivotal Study301 and subsequent observational studies. Further data from adequately-sized, ad hoc trials on eribulin use in second line for mTNBC are warranted to confirm our findings.
Published: 2021
Full Text: View/download PDF

49. The Impact of the Hippo Pathway and Cell Metabolism on Pathological Complete Response in Locally Advanced Her2+ Breast Cancer: The TRISKELE Multicenter Prospective Study

Author: Eriseld Krasniqi, Francesca Sofia Di Lisa, Anna Di Benedetto, Maddalena Barba, Laura Pizzuti, Lorena Filomeno, Cristiana Ercolani, Nicola Tinari, Antonino Grassadonia, Daniele Santini, Mauro Minelli, Filippo Montemurro, Maria Agnese Fabbri, Marco Mazzotta, Teresa Gamucci, Giuliana D’Auria, Claudio Botti, Fabio Pelle, Flavia Cavicchi, Sonia Cappelli, Federico Cappuzzo, Giuseppe Sanguineti, Silverio Tomao, Andrea Botticelli, Paolo Marchetti, Marcello Maugeri-Saccà, Ruggero De Maria, Gennaro Ciliberto, Francesca Sperati, and Patrizia Vici
Subjects: Cancer Research, Hippo pathway, cell metabolism, Her2−positive breast cancer, pathological complete response, Oncology
Abstract: The Hippo pathway and its two key effectors, Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ), are consistently altered in breast cancer. Pivotal regulators of cell metabolism such as the AMP-activated protein kinase (AMPK), Stearoyl-CoA-desaturase 1 (SCD1), and HMG-CoA reductase (HMGCR) are relevant modulators of TAZ/YAP activity. In this prospective study, we measured the tumor expression of TAZ, YAP, AMPK, SCD1, and HMGCR by immunohistochemistry in 65 Her2+ breast cancer patients who underwent trastuzumab-based neoadjuvant treatment. The aim of the study was to assess the impact of the immunohistochemical expression of the Hippo pathway transducers and cell metabolism regulators on pathological complete response. Low expression of cytoplasmic TAZ, both alone and in the context of a composite signature identified by machine learning including also low nuclear levels of YAP and HMGCR and high cytoplasmic levels of SCD1, was a predictor of residual disease in the univariate logistic regression. This finding was not confirmed in the multivariate model including estrogen receptor > 70% and body mass index > 20. However, our findings were concordant with overall survival data from the TCGA cohort. Our results, possibly affected by the relatively small sample size of this study population, deserve further investigation in adequately sized, ad hoc prospective studies.
Published: 2022
Full Text: View/download PDF

50. The Impact of the Hippo Pathway and Cell Metabolism on Pathological Complete Response in Locally Advanced Her2+ Breast Cancer: The TRISKELE Multicenter Prospective Study

Author: Krasniqi, Eriseld, primary, Di Lisa, Francesca Sofia, additional, Di Benedetto, Anna, additional, Barba, Maddalena, additional, Pizzuti, Laura, additional, Filomeno, Lorena, additional, Ercolani, Cristiana, additional, Tinari, Nicola, additional, Grassadonia, Antonino, additional, Santini, Daniele, additional, Minelli, Mauro, additional, Montemurro, Filippo, additional, Fabbri, Maria Agnese, additional, Mazzotta, Marco, additional, Gamucci, Teresa, additional, D’Auria, Giuliana, additional, Botti, Claudio, additional, Pelle, Fabio, additional, Cavicchi, Flavia, additional, Cappelli, Sonia, additional, Cappuzzo, Federico, additional, Sanguineti, Giuseppe, additional, Tomao, Silverio, additional, Botticelli, Andrea, additional, Marchetti, Paolo, additional, Maugeri-Saccà, Marcello, additional, De Maria, Ruggero, additional, Ciliberto, Gennaro, additional, Sperati, Francesca, additional, and Vici, Patrizia, additional
Published: 2022
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

1,117 results on '"Gamucci, A."'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources